search
Back to results

Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection (SINBIOSE-H)

Primary Purpose

Hip Prosthesis Infection

Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Defensive Antiadhesive Coating DAC®, Novagenit SRL
Sponsored by
Centre Hospitalier Universitaire de Saint Etienne
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hip Prosthesis Infection focused on measuring Surgery, Biofilm inhibitor, Chronic infections, Total Hip Arthroplasties (THA), Defensive Antibacterial Coating (DAC®), Novagenit®, Hip Prosthesis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Social security affiliation
  • Signed informed consent
  • Chronic periprosthetic hip joint infection defined according to the Musculoskeletal Infection Society criteria :
  • Two positive periprosthetic cultures with phenotypically identical organisms
  • or a sinus tract communicating with the joint,
  • or having 3 of 5 minor criteria:

    • Elevated serum C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR);
    • Elevated synovial fluid White Blood Cell (WBC) count or change of ++ on leukocyte esterase test strip;
    • Elevated synovial fluid Polymorphonuclear Neutrophil Percentage (PMN%);
    • Positive histological analysis of periprosthetic tissue;
    • A single positive culture.

Exclusion Criteria:

  • Patients with hypersensitivity to hydrogel components (hyaluronic acid and/or poly-lactic acid) known of Defensive Antibacterial Coating (DAC)®
  • Pregnancy or positive pregnancy test (performed in women of childbearing age before inclusion)
  • Life expectancy < 3 months
  • Expected use of a cemented implant by the surgical team (for the treatment surgical protocol)
  • Unable to give informed consent
  • Patients under guardianship or curators
  • Refusal to participate

Sites / Locations

  • CHU Amiens
  • CHU Bordeaux
  • CHU Caen
  • CHU Clermont-Ferrand
  • CHU Dijon
  • CHU Lille
  • HCL - Hôpital de la Croix Rousse
  • HCL - Hôpital Edouard Herriot
  • CHU Marseille
  • CHU Nancy
  • CHU Nantes
  • CHU Nice
  • Chu Saint-EtienneRecruiting
  • CHU Toulouse

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Single-stage surgery + DAC® + topical antibiotics

control group : two-stage surgery

Arm Description

Experimental group is composed of single-stage procedure associated to the use of biofilm inhibitor (Defensive Antibacterial Coating® DAC®) and topical antibiotics=new strategy

Control group is composed of two-stage procedure without biofilm inhibitor (standard protocol)

Outcomes

Primary Outcome Measures

Recurrence of clinically diagnosed infection relapse of the periprosthetic joint
The periprosthetic joint infection is defined according to the Musculoskeletal Infection Society criteria: Two positive periprosthetic cultures with phenotypically identical organisms or a sinus tract communicating with the joint, or having 3 of 5 minor criteria: Elevated serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR); Elevated synovial fluid white blood cell (WBC) count; Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%); Positive histological analysis of periprosthetic tissue; A single positive culture.

Secondary Outcome Measures

Harris Hip Score (HHS) results
Harris Hip Score (HHS) contains 10 items with maximum score at 100 for a perfect hip and minimum score at 0 for a very bad result.
Postel-Merle d'Aubigné (PMA) results
Postel-Merle d'Aubigné (PMA) contains 3 items (pain, mobility and functional hip) with maximum score at 18 for a perfect hip and minimum score at 0 for a very bad result.
Hip dysfunction and Osteoarthritis Outcome Score (HOOS) results
Hip dysfunction and Osteoarthritis Outcome Score contains 6 items (symptoms, stiffness, pain, function and daily life, sport and leisure activities, quality of life) and measure everyday activities with score from 0 to 4.
Oxford-12 results
Oxford-12 allows to know the feelings of the patient during the last 4 weeks felt from 1 to 5 (satisfaction score).
Death rate (%)
Analysis of death rate by group.
Post-operative complications
Analysis of post-operative complications by group.
Revision surgery for any cause other than infection
Analysis of revision surgery for any cause other than infection.

Full Information

First Posted
January 30, 2020
Last Updated
December 13, 2022
Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Collaborators
Ministry of Health, France
search

1. Study Identification

Unique Protocol Identification Number
NCT04251377
Brief Title
Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection
Acronym
SINBIOSE-H
Official Title
Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection SINBIOSE-H.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
September 30, 2021 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Collaborators
Ministry of Health, France

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Each year, around 1500 infected Total Hip Arthroplasties (THA) need non-conservative surgery, remaining an issue for patients and healthcare units. The recommended treatment, relying on cohort reviews and international consensus follows a two-stage protocol. This protocol implies a first surgery to remove all infected implants and at least 6 weeks of antibiotic treatment without implant, then usually an antibiotic-free period and only then a second surgery to put back new implants and start the rehabilitation protocol, with usually more than a week of a second hospital stay. Between both surgeries, full-weight bearing is prohibited and joint stiffness and/or pain are rather usual complications. Failure rate is estimated at 10% in this two-stage strategy. The single-stage procedure (i.e. implanting back a new prosthesis during the same surgery after implant removal, synovectomy and lavage) is thought to be less susceptible to late functional complications (i.e. pain, stiffness and muscle deficiency) with a shorter, single hospital stay. Although, with single-stage surgery, infection control could be less efficient because most pathogens produce during the first hours of infection an antibiotic-resistant layer called biofilm, allowing them to colonize and adhere to foreign objects like implants. This single-surgery protocol thus highly relies on antibiotics and has a list of contra-indications (based on experts' consensus): the presence of damaged soft tissues or a sinus tract, unknown pathogens, difficult to treat micro-organisms, severe immunosuppression and for many surgeons, each time a bone graft is necessary. Most of these contra-indications are directly related to the biofilm. As no randomized control trial has ever compared single-stage versus two-stage surgery, the level of evidence for recommending one procedure over the other is low. We conducted a survey that showed that most of the French reference centers have already switched to single stage surgery for single-stage non contra-indicated cases. An antibiotic-loaded hydrogel coating (Defensive Antiadhesive Coating®, Novagenit SRL), has been proven to mechanically prevent the biofilm formation, while allowing a prolonged intraarticular antibiotic release, in a randomized controlled trial in primary prevention of infection in THA. The addition of this biofilm inhibitor to a single-stage surgery might stand as a promising strategy for secondary prevention of peri-prosthetic hip joint infection. Moreover, using this device to prevent biofilm formation could expand one stage surgery to patients that are "normally" contra-indicated to one stage surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hip Prosthesis Infection
Keywords
Surgery, Biofilm inhibitor, Chronic infections, Total Hip Arthroplasties (THA), Defensive Antibacterial Coating (DAC®), Novagenit®, Hip Prosthesis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
440 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Single-stage surgery + DAC® + topical antibiotics
Arm Type
Experimental
Arm Description
Experimental group is composed of single-stage procedure associated to the use of biofilm inhibitor (Defensive Antibacterial Coating® DAC®) and topical antibiotics=new strategy
Arm Title
control group : two-stage surgery
Arm Type
No Intervention
Arm Description
Control group is composed of two-stage procedure without biofilm inhibitor (standard protocol)
Intervention Type
Device
Intervention Name(s)
Defensive Antiadhesive Coating DAC®, Novagenit SRL
Intervention Description
DAC gel, mixed with topical antibiotics is applied on the surface of the implants before implantation, in a sterile environment in the operating room. The topical antibiotics will be added to the reconstituted DAC® gel preparation, at the discretion of the physician, on the basis of pre-operative culture.
Primary Outcome Measure Information:
Title
Recurrence of clinically diagnosed infection relapse of the periprosthetic joint
Description
The periprosthetic joint infection is defined according to the Musculoskeletal Infection Society criteria: Two positive periprosthetic cultures with phenotypically identical organisms or a sinus tract communicating with the joint, or having 3 of 5 minor criteria: Elevated serum C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR); Elevated synovial fluid white blood cell (WBC) count; Elevated synovial fluid polymorphonuclear neutrophil percentage (PMN%); Positive histological analysis of periprosthetic tissue; A single positive culture.
Time Frame
Years : 2
Secondary Outcome Measure Information:
Title
Harris Hip Score (HHS) results
Description
Harris Hip Score (HHS) contains 10 items with maximum score at 100 for a perfect hip and minimum score at 0 for a very bad result.
Time Frame
Years : 2
Title
Postel-Merle d'Aubigné (PMA) results
Description
Postel-Merle d'Aubigné (PMA) contains 3 items (pain, mobility and functional hip) with maximum score at 18 for a perfect hip and minimum score at 0 for a very bad result.
Time Frame
Years : 2
Title
Hip dysfunction and Osteoarthritis Outcome Score (HOOS) results
Description
Hip dysfunction and Osteoarthritis Outcome Score contains 6 items (symptoms, stiffness, pain, function and daily life, sport and leisure activities, quality of life) and measure everyday activities with score from 0 to 4.
Time Frame
Years : 2
Title
Oxford-12 results
Description
Oxford-12 allows to know the feelings of the patient during the last 4 weeks felt from 1 to 5 (satisfaction score).
Time Frame
Years : 2
Title
Death rate (%)
Description
Analysis of death rate by group.
Time Frame
Years : 2
Title
Post-operative complications
Description
Analysis of post-operative complications by group.
Time Frame
Years : 2
Title
Revision surgery for any cause other than infection
Description
Analysis of revision surgery for any cause other than infection.
Time Frame
Years : 2

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Social security affiliation Signed informed consent Chronic periprosthetic hip joint infection defined according to the Musculoskeletal Infection Society criteria : Two positive periprosthetic cultures with phenotypically identical organisms or a sinus tract communicating with the joint, or having 3 of 5 minor criteria: Elevated serum C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR); Elevated synovial fluid White Blood Cell (WBC) count or change of ++ on leukocyte esterase test strip; Elevated synovial fluid Polymorphonuclear Neutrophil Percentage (PMN%); Positive histological analysis of periprosthetic tissue; A single positive culture. Exclusion Criteria: Patients with hypersensitivity to hydrogel components (hyaluronic acid and/or poly-lactic acid) known of Defensive Antibacterial Coating (DAC)® Pregnancy or positive pregnancy test (performed in women of childbearing age before inclusion) Life expectancy < 3 months Expected use of a cemented implant by the surgical team (for the treatment surgical protocol) Unable to give informed consent Patients under guardianship or curators Refusal to participate
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bertrand BOYER, MD
Phone
(0)477120820
Ext
+33
Email
bertrand.boyer@chu-st-etienne.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Carine LABRUYERE, CRA
Phone
(0)477120469
Ext
+33
Email
carine.labruyere@chu-st-etienne.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bertrand BOYER, MD
Organizational Affiliation
CHU SAINT-ETIENNE
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Amiens
City
Amiens
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benoit BRUNCHWEILER, PhD
Facility Name
CHU Bordeaux
City
Bordeaux
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thierry FABRE, PhD
First Name & Middle Initial & Last Name & Degree
Frédéric-Antoine DAUCHY, MD
Facility Name
CHU Caen
City
Caen
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Goulven ROCHCONGAR, MD
Facility Name
CHU Clermont-Ferrand
City
Clermont-Ferrand
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stéphane DESCAMPS, MD PhD
Facility Name
CHU Dijon
City
Dijon
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ludovic LABATTUT, MD
Facility Name
CHU Lille
City
Lille
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henri MIGAUD, MD
Facility Name
HCL - Hôpital de la Croix Rousse
City
Lyon
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sébastien LUSTIG, MD PhD
First Name & Middle Initial & Last Name & Degree
Cécile BATAILLER, MD PhD
Facility Name
HCL - Hôpital Edouard Herriot
City
Lyon
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Frédéric RONGIERAS, MD PhD
Facility Name
CHU Marseille
City
Marseille
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xavier FLECHER, PhD
Facility Name
CHU Nancy
City
Nancy
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Didier MAINARD, PhD
Facility Name
CHU Nantes
City
Nantes
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sophie TOUCHAIS, MD
First Name & Middle Initial & Last Name & Degree
Yoann VARENNE, MD
Facility Name
CHU Nice
City
Nice
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Régis DE DOMPSURE, MD
Facility Name
Chu Saint-Etienne
City
Saint-etienne
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bertrand BOYER, MD
Facility Name
CHU Toulouse
City
Toulouse
Country
France
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas REINA, PhD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Single-stage Surgery With Antibiotic-loaded Hydrogel Coated Implants Versus Two Stage Surgery for Secondary Prevention of Complex Chronic Periprosthetic Hip Joint Infection

We'll reach out to this number within 24 hrs